What were Sudeep Pharma Ltd's latest quarterly results?
Sudeep Pharma Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: +11.4% (turning around (inflection up))
- Revenue Growth YoY: +15.2%
- Operating Margin: 34.0% (volatile)
Sudeep Pharma Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +31.6%AverageNew This Week
In , Sudeep Pharma Ltd (Chemicals - Speciality) is outperforming Nifty 500 with +31.6% relative strength. Fundamentals: Average.
Sudeep Pharma Ltd Key Facts
- PE Ratio
- 56.4x
- Market Cap
- ₹9,745 Cr
- PAT Growth YoY
- +11%
- Revenue Growth YoY
- +15%
- OPM
- 34.0%
- RS vs Nifty 500
- +31.6%
Emerging Opportunity
What's Happening
⏳Steady earner with flat PE — waiting for re-rate catalyst
🏛️DII accumulation — stake up 2.5%
💰Trading 30% above estimated fair value — significant premium
Key Numbers
PAT Growth YoY
+11%
Inflection Up
Revenue YoY
+15%
Stable
Operating Margin
34.0%
-300 bps YoY
PE Ratio
56.4
Current Price
₹863
Dividend Yield
0.17%
Fundamental Score
46/100
Average
3Y PAT CAGR
+41%
Market Cap
9.7K Cr
Valuation
Significantly Overvalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
How Fast Is Sudeep Pharma Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +15% | +14% | Stable |
| PAT (Net Profit) | +11% | +41% | Inflection Up |
| OPM | 34.0% | -300 bps | Volatile |
Other Top Chemicals - Speciality Stocks Beating Nifty 500
Frequently Asked Questions: Sudeep Pharma Ltd
Based on publicly available financial data. This is educational research, not investment advice.
Is Sudeep Pharma Ltd's profit growing or declining?
Sudeep Pharma Ltd's profit is growing with a turning around (inflection up) trend.
- PAT Growth YoY: +11.4% (latest quarter)
- PAT Growth QoQ: +2.1% (sequential)
- 3-Year PAT CAGR: +41.0%
- Trend: Turning around (inflection up) — consistent growth pattern
What is Sudeep Pharma Ltd's revenue growth trend?
Sudeep Pharma Ltd's revenue growth trend is stable.
- Revenue Growth YoY: +15.2%
- Revenue Growth QoQ: +5.8% (sequential)
- 3-Year Revenue CAGR: +14.4%
How is Sudeep Pharma Ltd's operating margin trending?
Sudeep Pharma Ltd's operating margin is volatile.
- Current OPM: 34.0%
- OPM Change YoY: -3.0% basis points
- OPM Change QoQ: -1.0% basis points
What is Sudeep Pharma Ltd's 3-year profit and revenue CAGR?
Sudeep Pharma Ltd's long-term compounding rates
- 3-Year Profit CAGR: +41.0%
- 3-Year Revenue CAGR: +14.4%
Is Sudeep Pharma Ltd's growth accelerating or decelerating?
Sudeep Pharma Ltd's earnings growth is turning around (inflection up) with positive momentum on a sequential basis.
- YoY Acceleration: -54.1% bps
- Sequential Acceleration: 0.0% bps
- Margin Warning: Operating margins are under pressure
Is Sudeep Pharma Ltd overvalued or undervalued?
Sudeep Pharma Ltd appears significantly overvalued based on our fair value analysis.
- Valuation Signal: Significantly Overvalued
- Current PE: 56.4x
- Price-to-Book: 11.0x
What is Sudeep Pharma Ltd's current PE ratio?
Sudeep Pharma Ltd's current PE ratio is 56.4x.
- Current PE: 56.4x
- Market Cap: 9.7K Cr
- Dividend Yield: 0.17%
How does Sudeep Pharma Ltd's valuation compare to its history?
Sudeep Pharma Ltd's current PE is 56.4x.
- Current PE: 56.4x
- Valuation Assessment: Significantly Overvalued
What is Sudeep Pharma Ltd's price-to-book ratio?
Sudeep Pharma Ltd's price-to-book ratio is 11.0x.
- Price-to-Book (P/B): 11.0x
- Book Value per Share: ₹78
- Current Price: ₹863
Is Sudeep Pharma Ltd a fundamentally strong company?
Sudeep Pharma Ltd is rated Average with a fundamental score of 45.92/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +15.2% (10% weight)
- PAT Growth YoY: +11.4% (10% weight)
- PAT Growth QoQ: +2.1% (10% weight)
- Margins stable (10% weight)
Is Sudeep Pharma Ltd debt free?
Sudeep Pharma Ltd's debt position
- Total Debt: ₹150 Cr
What is Sudeep Pharma Ltd's return on equity (ROE) and ROCE?
Sudeep Pharma Ltd's return ratios over recent years
- FY2024: ROCE 49.0%
- FY2025: ROCE 36.0%
- FY2026: ROCE 28.0%
Is Sudeep Pharma Ltd's cash flow positive?
Sudeep Pharma Ltd's operating cash flow is positive (FY2026).
- Cash from Operations (CFO): ₹70 Cr
- Free Cash Flow (FCF): ₹-257 Cr
- CFO/PAT Ratio: 40% (weak cash conversion)
What is Sudeep Pharma Ltd's dividend yield?
Sudeep Pharma Ltd's current dividend yield is 0.17%.
- Dividend Yield: 0.17%
- Current Price: ₹863
Who holds Sudeep Pharma Ltd shares — promoters, FII, DII?
Sudeep Pharma Ltd's shareholding pattern (Jun 2026)
- Promoters: 76.2%
- FII (Foreign): 1.8%
- DII (Domestic): 15.6%
- Public: 6.4%
Is promoter holding increasing or decreasing in Sudeep Pharma Ltd?
Sudeep Pharma Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 76.2% (Jun 2026)
- Previous Quarter: 76.2% (Mar 2026)
- Change: 0.00% (stable)
How long has Sudeep Pharma Ltd been outperforming Nifty 500?
Sudeep Pharma Ltd has been outperforming Nifty 500 for 1 consecutive week, indicating early-stage outperformance.
Is Sudeep Pharma Ltd a new momentum entry or an established outperformer?
Sudeep Pharma Ltd is a new entry this week — it just started outperforming Nifty 500. New entries are worth monitoring for follow-through.
Is Sudeep Pharma Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Sudeep Pharma Ltd may be worth studying
- Earnings growing at +11.4% YoY
- Cash flow is positive — CFO ₹70 Cr
What is the investment thesis for Sudeep Pharma Ltd?
Sudeep Pharma Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +15.2% YoY
Risk Factors (Bear Case)
- Margins under pressure
- Appears significantly overvalued
What is the future outlook for Sudeep Pharma Ltd?
Sudeep Pharma Ltd's forward outlook based on current data signals
- Earnings Trend: turning around (inflection up)
- Revenue Trend: stable
- Margin Trend: volatile
- Valuation: Significantly Overvalued
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.